National Institute for Health and Clinical Excellence (NICE)
Health organisations working to incorporate NICE recommendations into NHS care to benefit thousands of patients who have had a stroke
An NHS workforce and resource impact statement published yesterday (17 July 2019) highlights the work being done by national partners to integrate changes recommended by NICE in its updated stroke guideline into routine NHS patient care.
The statement is the result of a collaboration between NICE, NHS England and NHS Improvement, NHS Clinical Commissioners, and Health Education England. It is designed to help commissioners and trusts understand the potential impact on the NHS workforce and resources of implementing specific NICE guidelines.
Stroke affects around 230 people per 100,000 each year, with over 80,000 people hospitalised per year in England. It is the single biggest cause of disability in adults, with an estimated annual cost to the NHS of £2.98 billion per year. A further £4.55 billion per year is estimated to be spent on social care for people who have had a stroke.
The workforce and resource impact statement estimates the costs to the NHS of increasing the provision of thrombectomy - a procedure to remove the blood clot causing the stroke - will be around £3.7 million in the first year, rising to £18.5 million in year 5. However, it is likely that these will be offset by cost savings for NHS and social care services of around £15.4 million in year 5 as a result of shorter hospital stays and reductions in future NHS supportive care and social care costs.
The potential increased costs of additional MRI requests for patients suspected of having a ‘mini-stroke’ – a transient ischaemic attack (TIA) - will be offset by savings gained through no longer routinely offering CT brain scanning to everyone with a suspected TIA. The net impact of these recommendations is estimated to be a cost saving of around £800,000 in year 5.
Overall, implementation of the guideline in England will cost around £18.6 million in 2023/24, although this will be offset by NHS and social care cost savings of around £16.2 million.
The statement also highlights the initiatives underway both within and across organisations to put the NICE guideline recommendations into practice, including support by NHS England specialised commissioning for the implementation of a thrombectomy service specification across the country. These initiatives will ensure the provision of the most effective, up-to-date treatments and in doing so will improve patient care.
Health Education England will work with the medical Royal Colleges and others to develop new training programmes for hospital consultants to offer mechanical thrombectomy.
In addition, the newly established Stroke Delivery Board (as part of the NHS Long Term Plan) includes a focus on increasing rates of thrombectomy, as well as improving the delivery of hyper-acute stroke pathways. Delivery and performance will be monitored and supported regionally by NHSE and the Getting it Right First Time (GIRFT) Stroke Programme.
The statement published yesterday was developed by a guideline resource and implementation (GRIP) panel, comprising members from NICE, Health Education England, NHS Clinical Commissioners, and NHS England and NHS Improvement.
The GRIP panel has been set up to focus on NICE guidelines that are most likely to have a substantial resource impact on the NHS - either where the total cost of implementing a guideline is likely to be more than £5 million per year, or where the cost of implementing a single recommendation within the guideline is likely to exceed £1 million per year.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE22/05/2020 15:10:00
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease18/05/2020 11:15:00
NICE recently (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
NICE draft guidance recommends new treatment option for people with early breast cancer07/05/2020 12:25:00
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer
New COVID-19 guideline on acute kidney injury07/05/2020 09:15:00
NICE has published a new COVID-19 rapid guideline on acute kidney injury (AKI).
NICE publishes latest wave of COVID-19 guidelines04/05/2020 13:33:00
The first is on the care of children and young people who are immunocompromised and the second on antibiotics for pneumonia in adults in hospital.
NICE joins international collaboratives to respond to the COVID-19 pandemic01/05/2020 09:15:00
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
NICE publishes two new COVID-19 guidelines24/04/2020 11:15:00
NICE has published 2 new rapid COVID-19 guidelines on the care of patients with suspected and confirmed COVID-19.
NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response14/04/2020 11:15:00
NICE recently (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19.
NICE publishes new COVID-19 guidelines on severe asthma, pneumonia, rheumatological disorders and symptom management06/04/2020 14:15:00
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.